Navigation Links
Prolexys Pharmaceuticals Initiates Phase 1 Study
Date:8/29/2007

Novel Agent Administered in First-In-Human Study to Cancer Patients

SALT LAKE CITY, Aug. 29 /PRNewswire/ -- Prolexys Pharmaceuticals, Inc. today announced that its first-in-humans Phase 1 study of PRLX 93936 has begun. This open-label trial is designed to evaluate the safety, pharmacokinetic and pharmacodynamic properties of PRLX 93936 in patients with advanced solid tumors. Study sites include TGen Clinical Research at Scottsdale Healthcare in Scottsdale, Arizona, and Tower Cancer Research Foundation in Beverly Hills, California. The first Phase 1 study will be a dose-escalating trial involving up to 36 patients.

"We are enthusiastic about our participation in the study of this interesting new agent with what appears to be a unique mechanism of action," said Dr. Daniel Von Hoff, Physician-in-Chief and Director of Clinical Research at TGen, and the principal investigator for the study at Scottsdale Healthcare. "Rarely have we seen pre-clinical anti-tumor effects that match those produced by PRLX 93936. We're very hopeful that this compound will have a therapeutic effect in patients with tumors that are non-responsive to existing therapeutic agents."

"The initiation of this Phase I clinical trial demonstrates our commitment to develop novel approaches to cancer therapies based on the company's proteomics technology platform," said David Clark, President and CEO of Prolexys.

"Based on the broad anti-cancer activity we have seen in pre-clinical models, we are looking forward to evaluating the potential anti-cancer activity in humans for this new drug candidate," stated Dr. Sudhir Sahasrabudhe, Prolexys' Chief Scientific Officer.

About PRLX 93936

PRLX 93936 is a structural analog of a compound called erastin, in-licensed by Prolexys from the MIT/ Whitehead Institute in January 2005. Erastin was identified as a potential anti-cancer therapeutic in a screen against cell lines engineered to differentially express several oncogenes (cancer genes), including activated RasV12 (Cancer Cell 3, 285-96, 2003). Extensive medicinal chemistry efforts at Prolexys resulted in the discovery of PRLX 93936, a small molecule that is approximately 100 times more potent and 1000 times more soluble than erastin. Application of the company's proprietary chemiproteomics discovery platform identified the mitochondrial outer membrane protein VDAC (Voltage Dependent Anion Channel) as a potential target of erastin (Nature 447: 864-868, 2007), and PRLX 93936.

PRLX 93936 was tested against a series of normal and tumor cell lines derived from tumors with dissimilar causative mutations, indicating potent and selective activity against a wide variety of tumors, many with activated Ras pathway. The compound showed robust tumor regression in a range of human tumor xenografts grown in immuno-compromised mice, including models of pancreatic (PANC-1), colon (DLD1), and ovarian (OVCAR5) cancers, and melanoma (SK-Mel-28), fibrosarcoma (HT-1080) and other solid tumors. PRLX 93936 produced efficacy ranging from tumor-growth inhibition to complete regression in a dose-dependent fashion.

About Prolexys

Prolexys Pharmaceuticals, Inc. is a privately held biopharmaceutical enterprise that discovers small molecules acting on novel targets. Its therapeutic focus is cancer. The Company's ability to identify and validate novel targets is driven by its technological leadership in the field of proteomics and the application of proteomics to drug discovery programs. For more information about Prolexys, please visit http://www.prolexys.com.


'/>"/>
SOURCE Prolexys Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... -- Research and Markets has announced the addition ... their offering. ... The report forecasts the global optical transceiver market to grow at ... The report covers the present scenario and the growth prospects of ... size, the report considers the revenue generated from the shipment of ...
(Date:12/9/2016)... , Dec. 9, 2016  RxWiki Inc., a ... and digital marketing strategies of thousands of pharmacies through ... won Austin Inno,s "50 on Fire" Award ... "We,re pleased to accept the award as one ... , Chief Executive Officer at RxWiki. "Our platform gives ...
(Date:12/8/2016)... 8, 2016 IRIDEX Corporation (NASDAQ: IRIX ... shares of common stock, $0.01 par value (the "Offering" with ... offering.  The final terms of the Offering will depend on ... there can be no assurance as to whether or when ... use the net proceeds it will receive from this offering ...
Breaking Medicine Technology:
(Date:12/9/2016)... New York, NY (PRWEB) , ... December 09, 2016 , ... ... that raises awareness for organ transplantation while encouraging readers to sign up as an ... for a lifesaving organ transplant. , An organ donor can save up to ...
(Date:12/9/2016)... ... 2016 , ... "I had a terrible time trying to get my grandson ... if the nebulizer had a more child-friendly design, then children would be more likely ... patent-pending NEBY to avoid the need to deliver medication via a nebulizer mask. The ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... distinction by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in ... and patient safety. Only a few hospitals and facilities have earned this distinction. ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for ... JMIR Medical Informatics . , Results of the comparative usability study demonstrate ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... CURE Media ... centers and advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat ... the announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored to team ...
Breaking Medicine News(10 mins):